接受肺叶或全肺切除术的肺癌中,磨玻璃密度影的预后意义随病理淋巴结状态而异
回顾性纳入2010年7月至2017年12月接受肺叶或全肺切除术的非小细胞肺癌患者1545例,按CT有无磨玻璃密度影(GGO)成分分为GGO组548例与实性组997例。GGO与病理淋巴结状态对5年无病生存(交互作用p=.006)和5年总生存(p=.02)存在交互作用;GGO组生存优于实性组仅见于pN0患者(5年DFS调整HR 0.63,p=.002;5年OS调整HR 0.47,p=.002),pN1/2患者中未见此优势。
要点
- GGO成分的有利预后仅见于病理淋巴结阴性(pN0)患者,pN1/2患者中未见生存优势。
- pN0患者中,GGO对5年DFS的有利作用限于cT1期(调整HR 0.48,95%CI 0.32-0.72,p<.001)。
- pN0患者中,GGO对5年OS的有利作用见于cT1/2期(调整HR 0.37,95%CI 0.20-0.68,p=.002)。
核心结论
- GGO仅在有病理淋巴结阴性(pN0)的患者中为生存的有利预测因素,其中DFS优势见于cT1期患者,OS优势见于cT1/2期患者。
研究设计与样本
- 回顾性研究,纳入2010年7月至2017年12月接受肺叶或全肺切除术的NSCLC患者1545例,按CT上有无GGO成分分为GGO组548例(pN0 457例、pN1/2 91例)与实性组997例(pN0 660例、pN1/2 337例),采用Cox回归评估交互作用。
关键影像表现/征象
- GGO组与实性组的划分依据为CT上是否存在GGO成分。
- GGO与病理淋巴结状态对5年DFS存在交互作用(p=.006),对5年OS也存在交互作用(p=.02)。
诊断标准与关键数值
- 多因素分析中,GGO组较实性组5年DFS更优仅见于pN0患者(调整HR 0.63,p=.002),pN1/2患者中未见。
- 多因素分析中,GGO组较实性组5年OS更优仅见于pN0患者(调整HR 0.47,p=.002),pN1/2患者中未见。
- pN0患者中,GGO对5年DFS的有利作用限于cT1期(调整HR 0.48,95%CI 0.32-0.72,p<.001),cT2期及以上未见。
- pN0患者中,GGO对5年OS的有利作用见于cT1/2期(调整HR 0.37,95%CI 0.20-0.68,p=.002),cT3/4期未见。
临床应用与阅片要点
- 阅片报告GGO成分时需结合病理淋巴结状态解读其预后意义,pN1/2患者中GGO未见生存优势。
- pN0患者中GGO的预后价值因cT分期而异:DFS优势限于cT1期,OS优势限于cT1/2期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To clarify the prognostic significance of a ground-glass opacity (GGO) component according to T category and pathological nodal status in patients with resectable non-small cell lung cancer (NSCLC).
METHODS: Patients who underwent lobectomy or pneumonectomy for NSCLC between July 2010 and December 2017 were retrospectively included. Patients were divided into GGO and solid groups based on the presence of a GGO component on CT. The effects on survival of interactions between GGO and (a) pathological nodal status (pN) and (b) cT category were evaluated using Cox regression.
RESULTS: Out of 1545 patients, 548 were classified into the GGO group (pN0: 457, pN1/2: 91) and 997 into the solid group (pN0: 660, pN1/2: 337). There were interactions between the presence of GGO and pathological nodal status on 5-year disease-free survival (DFS; p = .006) and 5-year overall survival (OS; p = .02). In multivariate analysis, better survival of patients in the GGO group than in the solid group was observed only in pN0 category (adjusted hazard ratio [HR], 0.63 for 5-year DFS; p = .002 and 0.47 for 5-year OS; p = .002), but not in pN1/2 category. Moreover, in those with pN0 category, the favorable prognostic value of GGO was limited to those with cT1 category for 5-year DFS (adjusted HR, 0.48; p < .001) and those with cT1/2 category for 5-year OS (adjusted HR, 0.37; p = .002).
CONCLUSIONS: GGO was a favorable predictor of survival only in patients with pN0 category, showing an advantage in DFS for those with cT1 category and OS for those with cT1/2 category.
KEY POINTS: • The presence of ground-glass opacity was associated with a favorable prognosis, only in pathological node-negative patients (5-year disease-free survival, p = .002; 5-year overall survival, p = .002). • Within pathological node-negative patients, the effect of ground-glass opacity on 5-year disease-free survival was valid in patients with cT1 category (adjusted hazard ratio, 0.48; 95% confidence interval, 0.32-0.72; p < .001), but not in patients with cT2 or above category. • Within pathological node-negative patients, the effect of ground-glass opacity on 5-year overall survival was valid in patients with cT1/2 category (adjusted hazard ratio, 0.37; 95% confidence interval, 0.20-0.68; p = .002), but not in patients with cT3/4 category.
引用
- Park, Lee, Choe, et al. Differences in the prognostic implication of ground-glass opacity on CT according to pathological nodal status in lung cancers treated with lobectomy or pneumonectomy. Eur Radiol. 2022. PMID: 35141781. doi:10.1007/s00330-022-08563-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。